text.skipToContent text.skipToNavigation

QIAseq Targeted RNA Panels

Digital RNAseq for gene expression profiling
  • Molecular barcodes remove PCR and library construction bias
  • Start with only 25 ng of total RNA
  • Simple 1 day library construction workflow
  • Use with any illumina or Thermo-Fisher NGS instrument

QIAseq Targeted RNA Panels have been developed as a Sample to Insight solution for quantitative gene expression profiling using RNAseq. These panels integrate molecular barcode technology and a two-stage PCR-based library preparation to deliver unbiased and accurate quantification for your digital RNA sequencing results. QIAseq Targeted Panels are wet-bench verified to ensure the highest quality of results.

Need a quote for your research project or would you like to discuss your project with our specialist team? Contact Us

Advanced search settings



Species:
Products
Product Product no. Cat. no. List price:
 
 
Show details
    varies
Can't order online?
To place an order via phone, email or for requesting a quote, please provide the product’s name, number and catalog number.

QIAseq Targeted RNA Panels are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.


0
Digital sequencing (molecular barcodes) principle

QIAseq Targeted RNA Panels use a digital sequencing method, whereby a unique 12-base random molecular barcode incorporated into the gene-specific primers (GSP1) is used in the first extension step (after mRNA is converted to cDNA). Thus, every extension event yields a unique combination of molecular barcode and target sequence. At the end of sequencing, the relative amount of each mRNA target is determined by the number of unique molecular barcode-target combinations that were sequenced, thereby eliminating PCR duplicates and amplification bias, resulting in more accurate, unbiased gene expression analysis.

1
One solution to overcome the challenges of gene expression profiling

The QIAseq Targeted RNA Panels have been developed as a Sample to Insight solution for quantitative gene expression profiling using RNAseq. The panels use molecular barcodes and a two-stage PCR-based integrated library preparation to overcome the challenge of PCR duplicates and amplification bias to deliver unbiased, accurate and reproducible gene expression results.

2
Unbiased and accurate gene quantification (A)

Different amounts (20 ng, 5 ng or 1.25 ng) of universal reference RNA were used to determine expression levels of three genes (BNIP1, CTNND2 and DAPK1) using targeted RNAseq. QIAseq digital RNA sequencing method (A; molecular barcode counts) showed accurate quantification of all three genes corresponding to different RNA input, whereas traditional targeted RNAseq (B; read counts) revealed PCR duplication limitation and yielded inaccurate quantification.

3
Unbiased and accurate gene quantification (B)
Different amounts (20 ng, 5 ng or 1.25 ng) of universal reference RNA were used to determine expression levels of three genes (BNIP1, CTNND2 and DAPK1) using targeted RNAseq. QIAseq digital RNA sequencing method (A; molecular barcode counts) showed accurate quantification of all three genes corresponding to different RNA input, whereas traditional targeted RNAseq (B; read counts) revealed PCR duplication limitation and yielded inaccurate quantification.
4
Proprietary primer design delivers gene-specific amplicons (>97% specificity)

Sequencing libraries were prepared using 1.25, 5 or 20 ng universal reference RNA and QIAseq Targeted RNA Panels, ranging from 12-plex to 1000-plex. Sequencing was performed on the Illumina MiSeq, dedicating 1 million reads per sample. Specificity is calculated as percent of trimmed and mapped reads that map to intended targets.

5
Unmatched uniformity (>97% of assays are within 20% of median molecular tag counts)
A 917-plex gene panel was used to prepare a library from 10 ng of NA12878 reference DNA. All assays were designed to be intra-exon, and are thus single copy on genomic DNA. This allows an estimation of the uniformity of amplicon performance in the library preparation step (e.g., every unique tag equals one captured copy). In terms of raw assay performance, 97.5% of assays are within 20% of mean/median molecular tag counts. For cataloged panels, any assay below 20% is redesigned and replaced. Molecular barcodes entirely remove this variation in RNAseq counting.
6
Simple procedure

Starting with 25 ng of total unfragmented RNA, cDNA is synthesized, and each cDNA molecule is tagged with a unique molecular barcode before any amplification. The uniquely tagged cDNA molecules then undergo a two-stage PCR step for enrichment and library construction. It takes only 6 hours from RNA sample to targeted library ready for sequencing.

7
Positive results with as little as 0.2 copies of RNA per cell

ERCC standards, at 86 to 705,500 copies, spiked into universal reference RNA sample and enriched using 384-plex QIASeq Targeted RNA Panel in three technical replicates. (A) Sensitivity measurement. Under standard conditions (20 ng RNA input, 0.5 million MiSeq reads), ≥~100 copies of ERCC transcripts were reliability detected, which is the equivalent of ~0.2 copies per cell. (B) Precision measurement. At >10 barcodes/gene, CV was less than 5% for all targets, indicating high technical reproducibility. This corresponds to ~100 copies target RNA in the sample.

8
High concordance with qPCR
Expression levels for 384 genes were determined by both QIAseq Targeted RNA Panel and qPCR for Human Brain Reference RNA (HBRR) and Universal Human Reference RNA (UHRR) samples. The expression levels determined by qPCR were normalized to the average of four housekeeping genes (ACTB, B2M, GAPDH and RPLP0) and fold change between the samples was calculated (HBRR/UHRR) for each gene. For QIAseq, the number of unique molecular barcodes per gene were counted and normalized to average number of molecular barcodes for the four housekeeping genes for each sample. The fold change for each gene was then calculated. The QIAseq Targeted RNA Panel and qPCR assays exhibit similar fold-changes in gene expression, highlighting the accuracy of QIAseq-results.
Performance

Principle
  • Traditional RNA sequencing methods suffer from PCR duplication and amplification bias, resulting in inaccurate gene expression analysis. By introducing molecular barcodes before any amplification takes place, QIAseq Targeted RNA Panels are able to eliminate this issue to deliver accurate and digital quantification of genes (see figure Unbiased and accurate gene quantification).
  • A unique feature of the QIAseq Targeted RNA Panels is the set of built-in control assays. The gDNA assays control for any gDNA contamination in the RNA sample to ensure reproducible results. The housekeeping gene (HKG) assays are used to normalize data, thereby making sample-to-sample and run-to-run comparisons possible.

 

Procedure
  • The QIAseq Targeted RNA Panels workflow begins with converting total RNA into cDNA (see figure Simple procedure). The workflow requires minimal RNA input: as little as 25 ng total RNA can be used. No enrichment or depletion steps are necessary. The molecular barcoding step makes use of molecularly barcoded gene-specific primer (GSP1) in a multiplex primer panel (targeting 12-1000 genes) and an input of 20ng of cDNA equivalent (cDNA made from 20 ng of total RNA). After the barcoding step, the uniquely tagged cDNA is purified over beads to remove residual primers, and a PCR is set up with a second pool of gene-specific adapter primers (GSP2) and the RS2 primer, which primes off of a common tag on the GSP1 primers. This reaction insures that intended targets are enriched sufficiently to be represented in the final library. The number of cycles is kept to a minimum to keep PCR-induced variations in amplification to a low level (any variations are easily corrected and accounted for with the molecular barcodes). Another quick cleanup with beads is performed, and a universal PCR is run with RS2 and FS2 primers, which also adds sample-indexing barcodes to each sample. A final cleanup with beads is performed and the library is complete, and ready for quantification and sequencing.
  • An integral component of the QIAseq Targeted RNA Panels is data analysis and insight. Data analysis modules have been developed that are comprehensive, yet easy to use. Using these modules require no bioinformatics expertise. Starting with raw reads directly off the sequencer, the QIAseq targeted RNA data analysis tools at QIAGEN’s GeneGlobe portal, provide you with gene counts and fold changes, as well as links for pathway analysis.
Applications
  • Gene expression profiling
  • Biomarker research
  • Confirmation of whole transcriptome sequencing data
  • Confirmation of microarray data

You are not authorized to download the resource

Scientific Posters (1)
References
0
fragment fix placeholder
Human Immuno-Oncology
Introduction
The Human Immuno-Oncology QIAseq Targeted RNA Panel profiles the expression of 990 genes relevant to host immune responses against tumors. Immunotherapy, now commonly known as the fourth pillar of cancer treatment, brings new hope to otherwise difficult cases. However, not all cancer types or all patients with the same cancer type respond equally to the same treatment, some patients regress only to relapse later, and some immunotherapy treatments cause side effects resembling autoimmune disorders. Therefore, basic research such as gene expression analysis is required and ongoing to better understand the biology of immuno-oncology and to discover more biomarkers to identify successfully responsive patients. For example, the expression of the immune checkpoint molecules in this panel on both tumor and immune cells prevents cellular immune responses from developing against tumor cells and as such may serve as potential biomarkers. Infiltration of the tumor microenvironment with the correct balance of active effector immune cells over suppressive dendritic or exhausted T cells most strongly correlates with effective immunotherapy and host immune responses. The several immune cell-specific and immune response-specific gene expression signatures in this panel have been all been used to examine immune response status. Finally, gene expression in other biological processes important to these immune responses (such as antigen processing and presentation, the interferon gamma response, and the cytosolic DNA-sensing pathway) have also proven important to analyze. Samples used for such analyses include whole tumor biopsies, tumor or immune cells sorted from those biopsies and even immune cells sorted from whole blood as a noninvasive surrogate. Gene expression changes over immunotherapy treatment courses correlate with either tumor regression and immunotherapy success or tumor resistance and immunotherapy failure. Using digital RNA sequencing, the expression of 990 genes with established roles in immuno-oncology can be analyzed with this primer pool.
Gene List

Immuno-Oncology QIAseq Targeted RNA Panel Functional Gene Groupings

 

Checkpoint Molecules:

Inhibitory on Tumor Cells: C10orf54, CD200, CD274, CD48, CD80, CD86, ITGAV, ITGB3, LGALS9, MICA, MICB, PDCD1LG2, TNFRSF14.

Stimulatory on Tumor Cells: CD40, CD40LG, CD48, CD70, CD86, ICOSLG, TNFRSF9, TNFSF14, TNFSF4, TNFSF9.

Inhibitory on T Cells: BTLA, C10orf54, CD160, CD200R1, CD28, CD244, CD274, CTLA4, HAVCR2, KLRC1, LAG3, LILRB1, LILRB3, PDCD1.

Stimulatory on T Cells: CD244, CD27, CD28, CD40, CD40LG, ICOS, TNFRSF14, TNFRSF18, TNFRSF4, TNFRSF9, TNFSF14, TNFSF9.

T Cell Receptor Genes: CD247, CD3D, CD3E, CD3G, TRA, TRG.

Major Histocompatibility Complex I Genes: B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, MR1.

Major Histocompatibility Complex II Genes: CD74, IFI30, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5.

Other Checkpoint Molecules: ADORA2A, BTNL2, CD160, CD276, CD44, CD52, CD8A, HHLA2, IDO1, IDO2, KIR3DL1, KLRD1, LAIR1, MS4A1, NRP1, TIGIT, TMIGD2, TNFRSF25, TNFRSF8, TNFSF15, VTCN1.

 

Checkpoint Blockade Therapy Biomarkers: BTLA, CCR7, CD274, CD80, CD8A, CSF2, CTAG1A, CTAG1B, CXCL11, FIGF, HAVCR2, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, ICOS, IFNG, IL10, IL18, IL4, LAG3, MKI67, MLANA, PDCD1, PDCD1LG2, PTPRC.

 

Immuno Regulatory Gene Signature: BRDT, CCL11, CCL27, CD248, CD36, CLCF1, CSPG4, CTAGE5, CXCL1, CXCL14, CXCL2, CXCL3, EPHA2, ERBB2, FAP, FAS, IFNGR1, IL15, IL18, IL1RAP, IL5RA, IL6, INHBA, KDR, KIAA0100, MAGEA8, MLANA, MSLN, MYD88, PDGFRB, PRTN3, PSME3, SYCP1, TLR7, TNFRSF11A, TNFRSF8, TNFSF11, TNFSF4, TNFSF9, TPTE, VEGFC.

 

Immuno Stimulatory Gene Signature: ACVR1B, ACVR2B, AKAP3, AMHR2, AR, CBLB, CCDC33, CCL19, CCR10, CCR7, CD160, CD19, CD200, CD207, CD27, CD44, CD46, CD5, CD5L, CD7, CD82, CREB1, CRISP2, CTLA4, CXCL8, DCT, EPOR, EPPIN, GAGE1, HLA-A, IFNA1, IFNA14, IFNA21, IL12RB1, IL12RB2, IL13, IL13RA2, IL17A, IL17B, IL17RB, IL1R1, KIR3DL3, KIT, KLK3, MPL, ODF1, PIWIL2, PRM1, RFXAP, TNFRSF17, TNFSF18.

 

Immuno Suppressive Gene Signature: CD274, CD276, CD4, FIGF, HAVCR2, IL10, PDCD1LG2, TGFB1, TNFRSF10A, VEGFA, VEGFB, VEGFC.

 

Tumor Antigens: ACPP, AFP, ANKRD30A, CEACAM1, CEACAM16, CEACAM18, CEACAM19, CEACAM20, CEACAM21, CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CT83, CTAG1A, CTAG1B, DCT, EPCAM, GPR143, KLK3, MAGEA1, MAGEA3, MAGEA4, MLANA, MUC1, MUC16, PMEL, PRAME, RAB38, SCGB2A2, SPAG5, SSX2, TSSK6, TYR, TYRP1.

 

Upregulated in Cancer Vaccination Response: CCL5, CD3D, CD86, CD8A, CXCL10, CXCL2, CXCL9, FAM26F, GBP1, GBP5, GZMK, ICOS, IL2RG, IRF1, JAK2, KLRB1, KLRD1, PSMB9, STAT1.

 

Immune Cell Markers:

T Cells:

CD8 T Cells: ABT1, AES, APBA2, ARHGAP8, CAMLG, CD8A, CD8B, CDKN2AIP, DNAJB1, FLT3LG, GADD45A, GZMM, KAT6A, KLF9, LEPROTL1, LIME1, MAPKAPK5-AS1, PF4, PPP1R2, PRF1, PRR5, RBM3, SF1, SLC16A7, SRSF7, TBCC, THUMPD1, TMC6, TMEM259, TSC22D3, VAMP2, ZEB1, ZFP36L2, ZNF22, ZNF609, ZNF91.

 

Th1 Cells: APBB2, APOD, ATP9A, BST2, BTG3, CCL4, CD38, CD70, CMAHP, CSF2, CTLA4, DGKI, DOK5, DPP4, DUSP5, EGFL6, GGT1, HBEGF, IFNG, IL12RB2, IL22, LRP8, LRRN3, LTA, SGCB, STAT4, SYNGR3, TBX21, ZBTB32.

 

Th17 Cells: IL17A, IL17RA, RORC.

 

Th2 Cells: ADCY1, AHI1, ANK1, BIRC5, CDC25C, CDC7, CENPF, CXCR6, DHFR, EVI5, GATA3, GSTA4, HELLS, IL26, LAIR2, LIMA1, MAF, MB, MICAL2, NEIL3, PHEX, PMCH, PTGIS, SLC39A14, SMAD2, SNRPD1, WDHD1.

 

Follicular Helper T Cells: B3GAT1, CDK5R1, CHGB, CHI3L2, CXCL13, CXCR5, HEY1, HIST1H4K, ICA1, KCNK5, KIAA1324, LDLRAD4, MAF, MAGEH1, MKL2, MYO6, MYO7A, PASK, PDCD1, POMT1, PTPN13, PVALB, SH3TC1, SIRPG, SLC7A10, SMAD1, ST8SIA1, STK39, THADA, TOX, TSHR, ZNF764.

 

Other T Helper Cell Markers: ANP32B, ASF1A, ATF2, BATF, BORA, CD28, CD4, DDX50, FAM111A, FRYL, GOLGA8A, ICOS, ITM2A, LRBA, NAP1L4, NUP107, PHF10, PPP2R5C, RPA1, SEC24C, SLC25A12, UBE2L3, YME1L1.

 

Regulatory T Cells: FOXP3, IL2RA, KLF2, LRRC32.

 

Gamma Delta T Cells: C1orf61, CD160, FEZ1, TARP.

 

Central Memory T Cells: AQP3, ATF7IP, ATM, CASP8, CDC14A, CEP68, CLUAP1, CREBZF, CYLD, DOCK9, FAM153B, FOXP1, FYB, INPP4B, KLF12, KMT2A, MAP3K1, NEFL, NFATC3, PCM1, PCNX, PDXDC2P, PHC3, POLR2J2, PSPC1, REPS1, RPP38, SLC7A6, SNRPN, ST3GAL1, STX16, TIMM8A, TRAF3IP3, TXK, USP9Y.

 

Effector Memory T Cells: AKT3, CCR2, DDX17, EWSR1, FLI1, GDPD5, LTK, MEFV, NFATC4, PRKY, SND1-IT1, TBC1D5, TBCD.

 

Other T Cell Markers: BCL11B, CD14, CD2, CD247, CD3D, CD3E, CD3G, CD5, CD6, CD96, CHRM3-AS2, GIMAP5, IL2RB, LCK, MAL, MGC40069, NCALD, PBX4, PRKCQ, SH2D1A, SKAP1, THEMIS, TNFRSF25, TRAT1, ZAP70.

 

Myeloid Derived Suppressor Cells: ANPEP, ARG1, CD33, CD34, FUT4, IL10, ITGAM, TGFB1.

 

Cytotoxic Lymphocytes: APBA2, APOL3, CD3E, CD3G, CD4, CD8A, CD8B, CTSW, DUSP2, EOMES, FGFBP2, GNLY, GZMA, GZMB, GZMH, GZMK, IFNG, KLRB1, KLRC1, KLRC2, KLRC3, KLRC4, KLRD1, KLRF1, KLRK1, NKG7, RORA, RUNX3, SIGIRR, TBX21, ZBTB16.

 

Natural Killer Cells: ADARB1, ALDH1B1, APBB2, ATL2, BCL2, CD160, CDC5L, DUSP4, FGF18, FOXJ1, FUT5, FZR1, GAGE2A, GTF3C1, GZMB, IGFBP5, IL21R, KANK2, KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DS1, LDB3, LPCAT4, MADD, MAPRE3, MARCH6, MCM3AP, MPPED1, MRC2, NCR1, PDLIM4, PLA2G6, PPP4R3A, PRX, PSMD4, PTGDR, RRAD, SGMS1, SH2D1B, SLC30A5, SPN, SPON2, TBXA2R, TCTN2, TINAGL1, TRPV6, XCL1, XCL2, ZNF205, ZNF528, ZNF747.

 

Dendritic Cells:

Activated Dendritic Cells: CCL1, CD83, EBI3, LAMP3, OAS3.

Immature Dendritic Cells: ABCG2, BLVRB, CARD9, CD1A, CD1B, CD1C, CD1E, CH25H, CLEC10A, CSF1R, CTNS, DCSTAMP, F13A1, FABP4, FZD2, GSTT1, GUCA1A, HS3ST2, LMAN2L, MMP12, MS4A6A, NUDT9, PDXK, PPARG, PREP, RAP1GAP, SLC26A6, SLC7A8, SYT17, TACSTD2, VASH1.

Myeloid Dendritic Cells: CD1A, CD1B, CD1E, CLEC10A, CLIC2, WFDC21P.

Plasmacytoid Dendritic Cells: CLEC4C, IL3RA.

Other Dendritic Cell Markers: CCL13, CCL17, CCL22, CD209, HSD11B1, NPR1, PPFIBP2.

 

Macrophages: ANOS1, APOE, ATG7, BCAT1, CCL7, CD163, CD68, CD84, CHI3L1, CHIT1, CLEC5A, COL8A2, COLEC12, CTSK, CXCL5, CYBB, DNASE2B, EMP1, FDX1, FN1, GM2A, GPC4, MARCO, ME1, MS4A4A, MSR1, PCOLCE2, PPBP, PTGDS, RAI14, SCARB2, SCG5, SGMS1, SULT1C2.

 

Neutrophils: ALPL, BST1, CA4, CD93, CEACAM3, CREB5, CRISPLD2, CSF3R, CXCR1, CXCR2, CYP4F3, DYSF, FCAR, FCGR3B, FPR1, FPR2, G0S2, HAL, HIST1H2BC, HPSE, KCNJ15, LILRB2, MEGF9, MGAM, MME, PDE4B, S100A12, SIGLEC5, SLC22A4, SLC25A37, STEAP4, TECPR2, TLE3, TNFRSF10C, VNN3.

 

Eosinophils: ABHD2, ACACB, ADGRE1, C9orf156, CAT, CCR3, CLC, CYSLTR2, EPN2, GALC, HES1, HIST1H1C, HRH4, IL5RA, KBTBD11, KCNH2, LRP5L, MYO15B, PTGDR2, RCOR3, RNASE2, RRP12, SIAH1, SMPD3, SYNJ1, TGIF1, THBS1, THBS4, TIPARP, TKTL1.

 

Mast Cells: ABCC4, ADCYAP1, CALB2, CEACAM8, CMA1, CPA3, CTSG, GATA2, HDC, HPGD, HPGDS, KIT, MAOB, MLPH, MPO, MS4A2, NR0B1, PPM1H, PRG2, PTGS1, SCG2, SIGLEC6, SLC18A2, SLC24A3, TAL1, TPSAB1, TPSB2, VWA5A.

 

Other Monocytic Lineage Markers: ADAP2, CSF1R, FPR3, KYNU, PLA2G7, RASSF4, TFEC.

 

B Cells: ABCB4, BACH2, BANK1, BCL11A, BLK, BLNK, CCR9, CD19, CD22, CD72, CD79A, COCH, CR2, DTNB, FCRL2, GLDC, GNG7, HLA-DOB, HLA-DQA1, IGKC, KIAA0125, MEF2C, MICAL3, MS4A1, OSBPL10, PAX5, PNOC, QRSL1, SCN3A, SLC15A2, SPIB, TCL1A, TNFRSF17.

 

Regulatory T Cell Gene Signature: ACP5, ACSL4, ADAT2, ADPRH, AHCYL1, ANKRD10, BCL2L1, CADM1, CASP1, CCR8, CD177, CD274, CHRNA6, CHST2, CHST7, CREB3L2, CSF1, CSF2RB, CTSC, ENTPD1, ERI1, ETV7, FKBP1A, GCNT1, GRSF1, HS3ST3B1, HSDL2, HTATIP2, IKZF2, IKZF4, IL1R1, IL1R2, JAK1, KSR1, LAPTM4B, LAX1, LAYN, LEPROT, LY75, METTL7A, NAB1, NDFIP2, NETO2, NFAT5, NFE2L3, NPTN, PDCD1LG2, PRSS33, PTPRJ, RNF145, RRAGB, SLC35F2, SOCS2, SSH1, SSTR3, TFRC, TIGIT, TMEM184C, TMPRSS6, TNFRSF18, TNFRSF4, TNFRSF8, TNFRSF9, TRAF3, VDR, ZBTB38, ZNF282.

 

T Cell Trafficking & Infiltration into Tumors:

Stimulates T Cell Trafficking & Infiltration into Tumors: CCL5, CX3CL1, CXCL10, CXCL9, ICAM1, ITGB2, SELE, SELL, SELP.

Inhibits T Cell Trafficking & Infiltration into Tumors: EDNRB, FIGF, VEGFA, VEGFB, VEGFC.

Other T Cell Trafficking & Infiltration into Tumors Genes: CCL17, CCL19, CCL21, CCL25, CCL27, CCL3, CCL4, CCR10, CCR3, CCR4, CCR5, CCR6, CCR7, CCR9, CD274, CD44, CSF2, CXCL11, CXCL13, CXCR3, EDN1, EDN2, EDN3, EDNRA, F2, FOXP3, GLG1, IFNG, IL1A, IL1B, IL6, ITGA4, ITGAL, ITGB1, ITGB7, LAMP1, LAMP2, LTA, LTB, LTBR, MADCAM1, NOS3, NT5E, PDCD1, PDCD1LG2, PTEN, PTPRC, SELPLG, TLR7, TNF, TNFRSF25, TNFSF14, VCAM1.

 

T Cell Exhaustion:

Upregulated in T Cell Exhaustion: ATF4, ATP1B3, BST2, CBLB, CCL3, CCL5, CD200, CD27, CD69, CD7, CRTAM, CTLA4, CTSS, CXCL10, CXCL13, DCT, DGKE, EGR2, EIF3L, FAM3C, FASLG, FDFT1, FUT4, GBP1, GCH1, HIPK2, HLA-DMA, HLA-DQA1, ICOS, IFI16, IFIT3, IFNG, IFNGR1, IL10, INPP5F, IRF4, ITGAV, ITM2A, KCNK5, KIF3B, KLK3, MYO7A, NDFIP1, NFAT5, NR4A2, OTUD7B, PARK7, PTPRJ, RAB27A, RGS1, RGS16, RGS2, RNF19A, SH2D1A, SH2D2A, SIRPG, SLA, SP100, SPP1, STAT3, TAP1, THADA, TIGIT, TMBIM6, TNFRSF1B, TNFRSF9, TRAF3, UQCRC1, WARS, XCL2, ZC3H7A, ZNRF1.

Downregulated in T Cell Exhaustion: FGFBP2, ITGAM, TNFRSF25.

T Cell Exhaustion Transcriptional Nodes: BATF, NFATC1, PRDM1, TBX21.

Inhibits T Cell Exhaustion: IL2, IL21, IL7.

Enhances T Cell Exhaustion: IL10.

Other T Cell Exhaustion Signature Genes: ARL6IP5, CST7, EMP3, IFITM3, PC, SERPINB6, TRAF4.

 

Responsiveness or Response Biomarkers:

Enhanced Expression in Responsive Versus Nonresponsive Cancers: APP, CAPZB, CCL4, CCL5, CD8A, CSNK1E, CTLA4, CXCL10, CXCL11, CXCL9, EBI3, EHD1, GBA2, GZMB, HLA-DQA1, IDO1, IFNG, INHBA, IRF2, NKG7, ODF2, PHKG2, PPIF, PRF1, SERPINA3, SHMT2, SIGMAR1, SMAD3, TIA1.

Suppressed Expression in Responsive Versus Nonresponsive Cancers: ACTG1, BNIP3L, CX3CL1, FOXN3, IFI27, JAK1, LTA4H, NAIP, OPTN, PRRC2B, PTEN, RBL2, TXK.

Expression Correlates with Positive Objective Response Rates: CD274, CD276, CTLA4, HAVCR2, IDO1, LAG3, PDCD1LG2, VTCN1.

Upregulated during Treatment: CD8A, CTLA4, CXCL10, EOMES, GZMA, GZMB, ICOS, IFNG, PRF1, TNF.

Regulated during Treatment: ABR, BABAM1, CDA, COL3A1, CUL5, CXCL12, IRF1, LMO7, LPGAT1, MRPS27, NUMA1, RAD23A, RBBP8, SAR1B, SERPINA1, SMARCB1, SNTB2.

 

Cancer Cell Killing:

Inhibits Cancer Cell Killing: ARG1, ARG2, BTLA, C10orf54, CD274, CD80, HAVCR2, IDO1, IDO2, LAG3, MICA, MICB, PDCD1, TGFB1, TGFB2, TGFB3, VTCN1.

Stimulates Cancer Cell Killing: IFNG.

 

Antigen Processing & Presentation:

Proteasome: PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMB11, PSMC1, PSMC2, PSMC3, PSMC4, PSMC5, PSMC6, PSMD1, PSMD2, PSMD3, PSMD4, PSMD5, PSMD6, PSMD7, PSMD8, PSMD9, PSMD10, PSMD11, PSMD12, PSMD13, PSMD14, PSME1, PSME2, PSME3, PSME4, PSMF1, PSMG1, PSMG2, PSMG3, PSMG4.

Proteases: CTSB, CTSL, CTSS, ERAP1, ERAP2, IFI30, LGMN, LNPEP, NPEPPS, TPP2.

Endoplasmic Reticulum & Lysosomal Transport: ABCB9, TAP1, TAP2, TAPBP, TAPBPL.

Endoplasmic Reticulum Chaperones: CALR, CANX, PDIA3.

Major Histocompatibility Complex I Genes: B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, MR1.

Major Histocompatibility Complex II Genes: CD74, IFI30, HLA-DMA, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5.

Immune Cell Receptors & Co-Receptors: BCAP31, CD1D, CD4, CD8A, CD8B, KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3, KLRC1, KLRC2, KLRC3, KLRC4, KLRD1.

Stimulates Antigen Presentation: CD40, CD40LG, HMGB1, IFNA1, IFNA2, IL1A, IL1B, NT5C, TNF.

Inhibits Antigen Presentation: IL10, IL13, IL4.

 

Interferon Gamma Response:

Cell Adhesion Molecules: ICAM1, NCAM1, VCAM1.

Cytokines & Chemokines: CCL2, CCL5, IL12B, IL12RB1, IL18.

Innate Immune Response: CALCOCO2, NLRC5.

JAK / STAT Signaling: JAK2, PTPN1, PTPN11, PTPN2, SOCS1, SOCS3, STAT1.

Major Histocompatibility Complex I Genes: B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H.

Major Histocompatibility Complex II Genes: IFI30, HLA-DMA, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5.

Nitric Oxide Signaling: ARG2, ASS1, GCH1, NOS2.

Receptors: FCGR1A, FCGR1B, IFNGR1, IFNGR2, PTAFR, TLR3.

RNA Degradation: OAS1, OAS2, OAS3, OASL.

Transcription Factors: IRF1, IRF2, IRF3, IRF4, IRF5, IRF6, IRF7, IRF8, IRF9, PML, PPARG, SP100.

Other Interferon Gamma Response Genes: CD44, CIITA, GBP1, GBP2, GBP5, KYNU, MT2A, NUB1, SNCA, UBD, WNT5A.

 

Cytosolic DNA-Sensing Pathway:

Nucleic Acid Binding Proteins & Nucleases: ADAR, TREX1, ZBP1.

Inflammasome: AIM2, CASP1, PYCARD.

RIG-I-Like Receptor Signaling: DDX58, MAVS, MB21D1, TMEM173.

NFkB Signaling: CHUK, IKBKB, IKBKE, IKBKG, NFKB1, NFKBIA, NFKBIB, RELA, RIPK1, RIPK3, TBK1.

Transcription Factors: IRF3, IRF7.

Cytokines & Interferons: CCL4, CCL4L1, CCL4L2, CCL5, CXCL10, IFNA1, IFNA14, IFNA2, IFNA21, IFNB1, IL18, IL1B, IL33, IL6.

Gene Resource List
Format
pdf
FileSize
140KB
Download
Name Human Immuno-Oncology (RHS-009Z)

Customers who bought these products also bought

  • Cat No./ID: 333114
    /no/products//next-generation-sequencing/rna-sequencing/targeted-rna-panels/qiaseq-targeted-rna-indexes/

    QIAseq Targeted RNA 12-Index I (48)

    Kit containing sample indexes, enough for a total of 48 samples, for indexing up to 12 samples for targeted RNA sequencing on Illumina platforms (tube format), and primers necessary for sequencing RNA libraries generated by the QIAseq Targeted RNA Panels on Illumina platforms
    kr4,270.00
  • Cat No./ID: 333117
    /no/products//next-generation-sequencing/rna-sequencing/targeted-rna-panels/qiaseq-targeted-rna-indexes/

    QIAseq Targeted RNA 96-Index I (384)

    Kit containing sample indexes, enough for a total of 384 samples, for indexing up to 96 samples for targeted RNA sequencing on Illumina platforms (tube format), and primers necessary for sequencing RNA libraries generated by the QIAseq Targeted RNA Panels on Illumina platforms

    kr11,975.00